TCBP Awarded Non-Dilutive Funding, ScaleReady's G-Rex® Grant
Portfolio Pulse from
TC BioPharm (NASDAQ: TCBP) has received $250,000 in non-dilutive funding from the G-Rex® Grant Program, a $20M initiative by ScaleReady, Wilson Wolf Manufacturing, and Bio-Techne Corporation to advance cell and gene-modified cell therapy development.
November 12, 2024 | 2:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TC BioPharm has been awarded $250,000 in non-dilutive funding from the G-Rex® Grant Program to support its cell therapy development.
The non-dilutive funding of $250,000 from the G-Rex® Grant Program provides TC BioPharm with additional resources to advance its cell therapy development without diluting shareholder value. This positive financial support is likely to boost investor confidence and potentially lead to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100